Masashi Matsuyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masashi Matsuyama has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Nobuyuki Hizawa
17 shared publicationsChio Sakai
9 shared publicationsSosuke Matsumura
Department of Pulmonary Medicine, Institute of Medicine, University of Tsukuba
9 shared publicationsMasayuki Nakajima
Department of Pulmonary Medicine, Institute of Medicine, University of Tsukuba
7 shared publicationsMizu Nonaka
Department of Pulmonary Medicine, Institute of Medicine, University of Tsukuba
7 shared publicationsYuko Morishima
Department of Pulmonary Medicine, Institute of Medicine, University of Tsukuba
7 shared publications
Latest Publications
- 3 November 2026
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 64 Ā (6)
Successful tarlatamab treatment with concomitant oral corticosteroids and anticonvulsants in small-cell lung cancer with unstable brain metastases: A case report
- 3 November 2026
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 64 Ā (6)
Successful tarlatamab treatment with concomitant oral corticosteroids and anticonvulsants in small-cell lung cancer with unstable brain metastases: A case report
- Open Access
Mitochondria-Dependent Metabolic Reprogramming Enhances Myofibroblast Differentiation and Aggravates Bleomycin-Induced Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by irreversible fibrosis. Aberrant cell differentiation plays a crucial role in the development of IPF. Although recent studies have suggested that mitochondrial dysfunction may play a role in IPF, its direct impact on fibrosis remains unclear. This study aimed to clarify the role of mitochondria in lung cell differentiation and pulmonary fibrosis development by employing mito-mice ND6M, in which the activity of respiratory chain complex I is decreased due to a mitochondrial DNA mutation (G13997A). Pulmonary fibrosis was induced by administering bleomycin (BLM) to both wild-type and mito-mice ND6M. Bone marrow-derived macrophages and primary lung fibroblasts, generated from both types of mice, were analyzed to evaluate M1/M2 polarization and myofibroblast differentiation, respectively. Compared to wild-type mice, mito-mice ND6M exhibited more severe fibrosis and lower survival rates following BLM inoculation. Lactate production in the lungs after BLM administration was significantly higher in mito-mice ND6M than in wild-type mice. TGF-β1-treated fibroblasts from mito-mice ND6M exhibited increased α-smooth muscle actin expression. While type I collagen expression was not different between these mice, TGF-β1-induced expression of phosphoserine phosphatase and serine hydroxymethyltransferase2, two of the enzymes involved in the serineāglycine pathway, was significantly higher in mito-mice ND6M than in wild-type mice. On the other hand, mitochondrial dysfunction had a small effect on pulmonary inflammation and on M1/M2 macrophage polarization. In conclusion, mitochondrial dysfunction promotes TGF-β1-induced myofibroblast differentiation and BLM-induced pulmonary fibrosis. Mitochondria-dependent metabolic reprogramming may therefore represent a promising therapeutic target in IPF.
Open AccessMitochondria-Dependent Metabolic Reprogramming Enhances Myofibroblast Differentiation and Aggravates Bleomycin-Induced Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by irreversible fibrosis. Aberrant cell differentiation plays a crucial role in the development of IPF. Although recent studies have suggested that mitochondrial dysfunction may play a role in IPF, its direct impact on fibrosis remains unclear. This study aimed to clarify the role of mitochondria in lung cell differentiation and pulmonary fibrosis development by employing mito-mice ND6M, in which the activity of respiratory chain complex I is decreased due to a mitochondrial DNA mutation (G13997A). Pulmonary fibrosis was induced by administering bleomycin (BLM) to both wild-type and mito-mice ND6M. Bone marrow-derived macrophages and primary lung fibroblasts, generated from both types of mice, were analyzed to evaluate M1/M2 polarization and myofibroblast differentiation, respectively. Compared to wild-type mice, mito-mice ND6M exhibited more severe fibrosis and lower survival rates following BLM inoculation. Lactate production in the lungs after BLM administration was significantly higher in mito-mice ND6M than in wild-type mice. TGF-β1-treated fibroblasts from mito-mice ND6M exhibited increased α-smooth muscle actin expression. While type I collagen expression was not different between these mice, TGF-β1-induced expression of phosphoserine phosphatase and serine hydroxymethyltransferase2, two of the enzymes involved in the serineāglycine pathway, was significantly higher in mito-mice ND6M than in wild-type mice. On the other hand, mitochondrial dysfunction had a small effect on pulmonary inflammation and on M1/M2 macrophage polarization. In conclusion, mitochondrial dysfunction promotes TGF-β1-induced myofibroblast differentiation and BLM-induced pulmonary fibrosis. Mitochondria-dependent metabolic reprogramming may therefore represent a promising therapeutic target in IPF.
- Open Access
- 25 February 2026
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Immunology
- Vol.Ā 17, 1733057
The Nrf2-SLPI axis in aging and its role in the pathophysiology of pulmonary Mycobacterium avium complex disease
Aging is associated with a poor prognosis in pulmonary Mycobacterium avium complex (MAC) disease. This study aimed to elucidate the impact of aging on pulmonary MAC disease and its underlying mechanisms. Young and old mice were intranasally infected with Mycobacterium avium . RNA-seq analysis was performed on lung tissues to identify age-related gene expression changes. Whole blood cells from 100 untreated patients with pulmonary MAC disease were analyzed for SLPI mRNA expression and its association with age and disease severity. Old mice were more susceptible to MAC infection than young mice, with increased bacterial load and decreased expression of secretory leukocyte protease inhibitor (SLPI) in the lungs. SLPI showed direct antimicrobial activity against M. avium and was regulated by Nrf2, a transcription factor with reduced activity in infected old mice. Nrf2-deficient mice showed decreased SLPI expression and increased bacterial load. Treatment with sulforaphane restored SLPI expression and reduced bacterial burden in old mice. In humans, cluster analysis identified three clusters based on age and SLPI expression. Compared to cluster 1 (C1) (younger age and high SLPI), cluster C3 (older age and lower SLPI) had larger pulmonary lesions on computed tomography. Pathway analysis indicated reduced Nrf2 activation in C3 than in C1, consistent with the findings in the mouse experiments. The study suggests that age-related reductions in Nrf2 activity and SLPI expression contribute to poor outcomes in pulmonary MAC disease. Targeting the Nrf2-SLPI axis may represent a novel therapeutic approach for elderly patients.
- 25 February 2026
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Immunology
- Vol.Ā 17, 1733057
Open AccessThe Nrf2-SLPI axis in aging and its role in the pathophysiology of pulmonary Mycobacterium avium complex disease
Aging is associated with a poor prognosis in pulmonary Mycobacterium avium complex (MAC) disease. This study aimed to elucidate the impact of aging on pulmonary MAC disease and its underlying mechanisms. Young and old mice were intranasally infected with Mycobacterium avium . RNA-seq analysis was performed on lung tissues to identify age-related gene expression changes. Whole blood cells from 100 untreated patients with pulmonary MAC disease were analyzed for SLPI mRNA expression and its association with age and disease severity. Old mice were more susceptible to MAC infection than young mice, with increased bacterial load and decreased expression of secretory leukocyte protease inhibitor (SLPI) in the lungs. SLPI showed direct antimicrobial activity against M. avium and was regulated by Nrf2, a transcription factor with reduced activity in infected old mice. Nrf2-deficient mice showed decreased SLPI expression and increased bacterial load. Treatment with sulforaphane restored SLPI expression and reduced bacterial burden in old mice. In humans, cluster analysis identified three clusters based on age and SLPI expression. Compared to cluster 1 (C1) (younger age and high SLPI), cluster C3 (older age and lower SLPI) had larger pulmonary lesions on computed tomography. Pathway analysis indicated reduced Nrf2 activation in C3 than in C1, consistent with the findings in the mouse experiments. The study suggests that age-related reductions in Nrf2 activity and SLPI expression contribute to poor outcomes in pulmonary MAC disease. Targeting the Nrf2-SLPI axis may represent a novel therapeutic approach for elderly patients.
- Open Access
- 5 December 2025
- Published byĀ Springer NatureĀ inĀ BMC Pulmonary Medicine
- Vol.Ā 25 Ā (1)
Gender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases
Data on risk factors for discontinuation of nintedanib in patients with interstitial lung diseases (ILDs) are limited. The differences in tolerability betw
- 5 December 2025
- Published byĀ Springer NatureĀ inĀ BMC Pulmonary Medicine
- Vol.Ā 25 Ā (1)
Open AccessGender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases
Data on risk factors for discontinuation of nintedanib in patients with interstitial lung diseases (ILDs) are limited. The differences in tolerability betw
- 14 October 2025
- Published byĀ Oxford University Press (OUP)Ā inĀ American Journal of Respiratory and Critical Care Medicine
- Vol.Ā 212 Ā (3) , 625-641
Transcriptomic profiling in Mycobacterium avium complex pulmonary disease identifies clusters linked to disease severity and neutrophil activation
Rationale: Mycobacterium avium complex (MAC) pulmonary disease presents with heterogeneous clinical phenotypes. Objectives: This study aimed to elucidate the heterogeneity of MAC pulmonary disease by analyzing gene expression profiles in whole blood cells and identifying factors contributing to its pathogenesis, treatment response, and disease severity. Methods: A total of 100 patients with MAC pulmonary disease newly treated with guideline-based therapy (GBT) were analyzed prospectively, and RNA-sequencing was performed on whole blood cells. Unsupervised cluster analysis, differentially Āexpressed gene (DEG) analysis, and logistic least absolute shrinkage and selection operator regression were performed to identify key genes of the severe cluster. The expressions of these genes were validated in mice infected with M. avium bacteria. Measurements and Main Results: The cluster analysis identified 3 distinct patient clusters, each with unique clinical characteristic and treatment responses. Notably, Cluster 3 (C3) showed high neutrophil counts, older age, severe disease manifestations, and poor survival, despite sputum culture conversion. DEG analysis identified 6 neutrophil-related genes, FTH1, C19orf59 (MCEMP1), S100A9, SELL, ISG15, and IFITM1, as characteristic of C3. Furthermore, high expression of these genes correlated significantly with poor survival in both the present cohort and a previously reported cohort of pulmonary nontuberculous mycobacterial disease patients. M. avium infection increased S100A9 expression, particularly in old, but not young, mouse lungs, suggesting that increased S100A9 expression is associated with aging and infection. Conclusions: Gene expression profiling in MAC pulmonary disease patients identified 3 distinct clusters, with the most severe cluster characterized by neutrophil activation. Six genes were associated with disease severity and prognosis, though their causal roles require further investigation.
- 14 October 2025
- Published byĀ Oxford University Press (OUP)Ā inĀ American Journal of Respiratory and Critical Care Medicine
- Vol.Ā 212 Ā (3) , 625-641
Transcriptomic profiling in Mycobacterium avium complex pulmonary disease identifies clusters linked to disease severity and neutrophil activation
Rationale: Mycobacterium avium complex (MAC) pulmonary disease presents with heterogeneous clinical phenotypes. Objectives: This study aimed to elucidate the heterogeneity of MAC pulmonary disease by analyzing gene expression profiles in whole blood cells and identifying factors contributing to its pathogenesis, treatment response, and disease severity. Methods: A total of 100 patients with MAC pulmonary disease newly treated with guideline-based therapy (GBT) were analyzed prospectively, and RNA-sequencing was performed on whole blood cells. Unsupervised cluster analysis, differentially Āexpressed gene (DEG) analysis, and logistic least absolute shrinkage and selection operator regression were performed to identify key genes of the severe cluster. The expressions of these genes were validated in mice infected with M. avium bacteria. Measurements and Main Results: The cluster analysis identified 3 distinct patient clusters, each with unique clinical characteristic and treatment responses. Notably, Cluster 3 (C3) showed high neutrophil counts, older age, severe disease manifestations, and poor survival, despite sputum culture conversion. DEG analysis identified 6 neutrophil-related genes, FTH1, C19orf59 (MCEMP1), S100A9, SELL, ISG15, and IFITM1, as characteristic of C3. Furthermore, high expression of these genes correlated significantly with poor survival in both the present cohort and a previously reported cohort of pulmonary nontuberculous mycobacterial disease patients. M. avium infection increased S100A9 expression, particularly in old, but not young, mouse lungs, suggesting that increased S100A9 expression is associated with aging and infection. Conclusions: Gene expression profiling in MAC pulmonary disease patients identified 3 distinct clusters, with the most severe cluster characterized by neutrophil activation. Six genes were associated with disease severity and prognosis, though their causal roles require further investigation.
- Open Access
- 26 April 2025
- Published byĀ ElsevierĀ inĀ Respiratory Medicine Case Reports
- Vol.Ā 55, 102223
Compassionate use of tezepelumab in near fatal asthma: A case report and review of the literature
- 26 April 2025
- Published byĀ ElsevierĀ inĀ Respiratory Medicine Case Reports
- Vol.Ā 55, 102223
Open AccessCompassionate use of tezepelumab in near fatal asthma: A case report and review of the literature
- Open Access
- 15 March 2025
- Published byĀ Springer NatureĀ inĀ Cureus
- Vol.Ā 17 Ā (3) , e80607
Effect of Sitafloxacin and Amikacin Liposome Inhalation Suspension on Clarithromycin-Resistant Pulmonary Mycobacterium avium Complex Disease: A Case Series
Clarithromycin (CAM)-resistant pulmonary Mycobacterium avium complex (MAC) disease poses significant treatment challenges. This case series describes four patients treated with sitafloxacin (STFX) and amikacin liposome inhalation suspension (ALIS) in addition to standard guideline-based therapy (GBT). Sputum culture negativity was achieved in two patients, both under 65 years old and without cavitary lesions. These findings suggest the potential efficacy of STFX and ALIS as adjuncts to GBT for CAM-resistant pulmonary MAC disease, particularly in younger patients with non-cavitary disease.
- 15 March 2025
- Published byĀ Springer NatureĀ inĀ Cureus
- Vol.Ā 17 Ā (3) , e80607
Open AccessEffect of Sitafloxacin and Amikacin Liposome Inhalation Suspension on Clarithromycin-Resistant Pulmonary Mycobacterium avium Complex Disease: A Case Series
Clarithromycin (CAM)-resistant pulmonary Mycobacterium avium complex (MAC) disease poses significant treatment challenges. This case series describes four patients treated with sitafloxacin (STFX) and amikacin liposome inhalation suspension (ALIS) in addition to standard guideline-based therapy (GBT). Sputum culture negativity was achieved in two patients, both under 65 years old and without cavitary lesions. These findings suggest the potential efficacy of STFX and ALIS as adjuncts to GBT for CAM-resistant pulmonary MAC disease, particularly in younger patients with non-cavitary disease.
- Open Access
- 8 July 2024
- Published byĀ MDPI AGĀ inĀ Antioxidants
- Vol.Ā 13 Ā (7) , 818
Nrf2 Deficiency Accelerates IL-17-Dependent Neutrophilic Airway Inflammation in Asthmatic Mice
Asthma is a heterogeneous disease that can be broadly classified into type 2, which is primarily steroid-sensitive and eosinophilic, and non-type 2, which is primarily steroid-resistant and neutrophilic. While the mechanisms leading to the development of molecular-targeted therapies for type 2 asthma are being elucidated, much remains to be learned about non-type 2 asthma. To investigate the role of oxidative stress in refractory allergic airway inflammation, we compared asthma models generated by immunizing wild-type and nuclear factor erythroid-2-related factor 2 (Nrf2)-deficient mice with the house dust mite antigen. Both asthma models had similar levels of airway inflammation and hyperresponsiveness, but the Nrf2-deficient mice had increased oxidative stress and exacerbated neutrophilic airway inflammation compared with the wild-type mice. Type 2 cytokines and the expression of GATA3, a transcription factor that is important for Th2 cell differentiation, had decreased in Nrf2-deficient mice compared with the wild-type mice, whereas helper T (Th) 17 cytokines and the expression of RORγt, which is important for Th17 cell differentiation, had increased. Furthermore, the neutrophilic airway inflammation caused by Nrf2 deficiency was ameliorated by interleukin (IL)-17 neutralization. We have concluded that the disruption of the Nrf2-mediated antioxidant defense system contributed to the induction of Th17 differentiation and exacerbated allergic neutrophilic airway inflammation.
- 8 July 2024
- Published byĀ MDPI AGĀ inĀ Antioxidants
- Vol.Ā 13 Ā (7) , 818
Open AccessNrf2 Deficiency Accelerates IL-17-Dependent Neutrophilic Airway Inflammation in Asthmatic Mice
Asthma is a heterogeneous disease that can be broadly classified into type 2, which is primarily steroid-sensitive and eosinophilic, and non-type 2, which is primarily steroid-resistant and neutrophilic. While the mechanisms leading to the development of molecular-targeted therapies for type 2 asthma are being elucidated, much remains to be learned about non-type 2 asthma. To investigate the role of oxidative stress in refractory allergic airway inflammation, we compared asthma models generated by immunizing wild-type and nuclear factor erythroid-2-related factor 2 (Nrf2)-deficient mice with the house dust mite antigen. Both asthma models had similar levels of airway inflammation and hyperresponsiveness, but the Nrf2-deficient mice had increased oxidative stress and exacerbated neutrophilic airway inflammation compared with the wild-type mice. Type 2 cytokines and the expression of GATA3, a transcription factor that is important for Th2 cell differentiation, had decreased in Nrf2-deficient mice compared with the wild-type mice, whereas helper T (Th) 17 cytokines and the expression of RORγt, which is important for Th17 cell differentiation, had increased. Furthermore, the neutrophilic airway inflammation caused by Nrf2 deficiency was ameliorated by interleukin (IL)-17 neutralization. We have concluded that the disruption of the Nrf2-mediated antioxidant defense system contributed to the induction of Th17 differentiation and exacerbated allergic neutrophilic airway inflammation.
- Open Access
- 6 April 2024
- Published byĀ ElsevierĀ inĀ Allergology International
- Vol.Ā 73 Ā (3) , 473-476
Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
- 6 April 2024
- Published byĀ ElsevierĀ inĀ Allergology International
- Vol.Ā 73 Ā (3) , 473-476
Open AccessBlood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
- 15 September 2023
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 61 Ā (6) , 675-681
Patient profiling to predict response to bronchial thermoplasty in patients with severe asthma
- 15 September 2023
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 61 Ā (6) , 675-681
Patient profiling to predict response to bronchial thermoplasty in patients with severe asthma